A Multicenter, Randomized Trial of Photodynamic Therapy versus Argon Plasma Coagulation for Lung Cancer with Endobronchial Obstruction


This is a multi-center, randomized study that will compare the efficacy of photodynamic therapy (PDT) and argon plasma coagulation (APC) in the treatment of airway obstruction caused by non small cell lung cancer. Participants will be randomized in a 1:1 ratio to receive treatment with one of these two treatment modalities.

Inclusion Criteria:

  • Written informed consent obtained from the subject or the subject's legal representative and the ability for the subject to comply with all the study-related procedures.
  • Subjects must have a biopsy proven for non-small cell lung cancer with obstructing or partially obstructing endobronchial tumor involving the main stem bronchus or bronchus intermedius, with or without extrabronchial tumor.
  • Both males and females ≥ eighteen years of age
  • Subject must demonstrate at least a 50% airway stenosis due to endobronchial tumor.
  • Subject must demonstrate symptoms of cough, hemoptysis, dyspnea etc. attributable to partially or completely occluding endobronchial tumor.
  • Subject is able to tolerate multiple bronchoscopies.
  • Subjects who were previously treated with chemotherapy or radiotherapy are eligible for study entry. Such subjects must be at least 3 weeks post-chemotherapy and/or radiotherapy and must have recovered from all acute toxicities associated with such treatment.
  • A predicted life expectancy of at least 90 days.



Monetary compensation


Can be done from home



non-smal cell lung cancer, lung cancer, photodynamic therapy, argon plasma coagulation, airway obstruction

Principal Investigator

Michael Jantz, Clinical Associate Professor

Sponsoring Group

Department of Medicine


Department of Medicine

Contact Information


(352) 273-8737

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams